An observational study in Acute Coronary Syndrome, STEMI - ST-segment Elevation Myocardial Infarction and NSTEMI - Non-ST-Segment Elevation Myocardial Infarction, sponsored by Kitasato University. Recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2022-04-04.
Sponsored by Kitasato University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Acute Coronary Syndrome with a site in Japan — 3 open to participants now, 7 under way, 1 of them phase 3. Acute Coronary Syndrome · Japan.
Among the 33 studies in Acute Coronary Syndrome with a site in Japan, this one is one of 2 that started in 2012, is one of 8 observational ones, and was the 27th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →3 of the 33 studies in Acute Coronary Syndrome with a site in Japan are open now. Recruiting first, the newest first:
Stephen Nicholls · Sites in Japan, Australia, China and 6 more countries
Ages 18+
Fujita Health University · Sites in Japan
Ages 20+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,500 is above the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Median enrollment 2,000 across the 25 interventional studies, 527 across the 8 observational. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 33 have an industry lead sponsor. The 10 most frequent:
Kitasato University is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Kitasato University has 1 study filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Acute Coronary Syndrome with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT05325034Stephen NichollsGuideline Oriented Approach To Lipid Lowering In Asia-Pacific | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Acute Coronary Syndrome with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Kitasato PCI Registry is a single-center, observational, prospective study. This study aims to investigate the impact of characteristics in clinical manifestation, patients' background, procedure of percutaneous coronary intervention (PCI), and pre/post PCI culprit/nonculprit lesion observed by intra-coronary imaging modality on clinical outcomes.
Subjects who underwent PCI are eligible in this registry. The analysis for clinical characteristics, PCI procedural characteristics and findings of intra-coronary imaging including optical coherence tomography (OCT) and intravascular ultrasound (IVUS) is conducted. Subjects are clinically followed up to 5 years after the PCI.
Patients with coronary artery disease requiring PCI at Kitasato University Hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Culprit/nonculprit lesions are accessed by intra-coronary imaging device including intravascular ultrasound and optical coherence tomography.
Procedural characteristics include the information about angiographical characteristics, type of stent, pre/post POBA, and thrombectomy.
Device-oriented clinical end points (DoCE)
Composite of all-cause death, myocardial infarction, ischemic stroke, clinically indicated Composite of cardiac death, target lesion revascularization and stent thrombosis
Time frame: 5 years after the PCI
Major adverse cardiac and cerebrovascular events (MACCE)
Composite of all-cause death, myocardial infarction, ischemic stroke, clinically indicated coronary revascularization
Time frame: 5 years after the PCI
Plan to share: Undecided
Started Feb 2012 (actual). Primary completion is estimated for Mar 2025, 157 months after the start.
Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 157 months is above that.
Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kitasato University